Table of Contents
In today’s highly regulated and innovation-driven healthcare market, medtech companies often face the need to transfer manufacturing operations—whether due to geopolitical instability, cost pressure, lack of IP control, or the need for scaling. However, without proper manufacturing transfer support for medtech companies, the process can be plagued by hidden risks, missed deadlines, and even regulatory setbacks.
As an expert team that has developed over 150 medical and wellness devices across global markets, we’ve seen firsthand how critical the right approach is when transitioning manufacturing. This article breaks down key challenges and provides a blueprint for medtech teams to execute a smooth, compliant, and cost-effective manufacturing transfer.
What Is Manufacturing Transfer Support for Medtech Companies?
Manufacturing transfer support for medtech companies refers to the specialized technical, regulatory, and operational assistance provided to companies moving their device production from one facility to another. This may involve:
- Transferring production from a Chinese OEM to an in-house or regional partner
- Switching contract manufacturers due to quality or IP concerns
- Scaling up from pilot to commercial production
- Moving manufacturing closer to core markets for faster distribution or regulatory access
A successful transfer requires deep knowledge in engineering, quality systems, documentation, compliance (FDA, MDR, ISO 13485), and supplier management.
Why Medtech Manufacturing Transfers Are Uniquely Risky
Unlike in consumer electronics or fashion, medtech products must meet stringent safety, efficacy, and traceability requirements. Transferring manufacturing without expert support can lead to:
- Loss of critical documentation: In many China-based OEM models, clients receive finished products but not design files, firmware source code, or validated test protocols.
- Regulatory non-compliance: Even minor changes in processes or suppliers must be revalidated under FDA or MDR guidelines.
- Production delays: Lack of transfer planning can cause months of downtime and expensive firefighting.
- Unanticipated costs: Without a proper feasibility study, companies underestimate hours needed to reverse engineer or revalidate.
Explore more services of OVA Solutions here: ovasolutions.com
Phase-by-Phase Blueprint for Safe Manufacturing Transfer
1. Pre-transfer Assessment and IP Audit
- Map all components, software, BOMs, and suppliers
- Check availability of design history file (DHF), device master record (DMR), and source files
- Evaluate current QA/QC processes, and perform a gap analysis
2. Reverse Engineering and Redesign (If Needed)
If your current manufacturer won’t release source files, your team or partner must reconstruct:
- Electrical schematics
- Mechanical drawings
- Embedded software (often only binaries are available)
- Test protocols and manufacturing procedures
3. Documentation and Validation Package Creation
- Compile missing DHF/DMR documents
- Prepare new process validations (IQ/OQ/PQ)
- Ensure full traceability and documentation for regulatory submissions
4. Pilot Runs and Process Qualification at New Site
- Conduct engineering builds with DVT/PVT iterations
- Train new contract manufacturer staff or your internal team
- Perform full process qualification per ISO and FDA standards
5. Regulatory and Supply Chain Handover
- Submit required change notifications (e.g., FDA Q-Sub or CE Technical File update)
- Build out supply chain redundancy for critical parts
- Set up post-market surveillance processes under new production location
Real-World Example: Recovering IP and Reducing Time-to-Market
One of our clients, a US-based medtech startup, relied on a Chinese OEM to produce their connected orthopedic wearable. When they decided to relocate production due to IP concerns and investor pressure, they discovered they only had PDFs and a single binary firmware file.
We supported them by reverse-engineering the PCB, extracting functionality specs, rewriting embedded firmware from scratch, and rebuilding a validated design within 4 months. This cut their estimated delay by over 6 months and enabled them to raise their next round of funding.
| Insight / Tip | Category | Actionable Step |
|---|---|---|
| Always request the full Design History File (DHF) before signing any manufacturing agreement | Legal/IP | Include a DHF delivery clause with penalties for non-compliance |
| If you’re only getting binaries from your OEM, assume you have zero firmware control | Firmware | Prepare for a full rewrite or emulate missing functionality |
| Chinese OEMs reuse IP cores across multiple clients—your device may not be unique | IP Risk | Do a teardown and compare against similar devices online |
| Request manufacturer-level BOMs (with MPNs) instead of supplier-level lists | BOM Strategy | Ask for datasheets and supplier sources for each component |
| OEMs often “optimize” designs for their factory, not for your scaling or compliance goals | Production Transfer | Request CAD files of test jigs and fixtures before ending your contract |
| Never trust ISO/CE certificates at face value | Compliance | Verify in FDA MAUDE or official notified body databases |
| If gerber files are missing, use X-ray or micro-CT to reverse-engineer PCBs | Reverse Engineering | Hire a lab with 3D imaging and multilayer board expertise |
| Region-locked firmware is common and often non-editable legally | Firmware Legal Risk | Talk to IP counsel before attempting to change binary firmware |
| Revalidation takes longer than you think—minimum 1,500 hours for Class II devices | Regulatory Timeline | Allocate 4–6 months just for validation and documentation rebuild |
| Some markets won’t reimburse for Chinese-origin products | Market Access | Check CMS/NHS or reimbursement catalogues before committing |
| Injection molds are rarely included in your IP by default | Tooling/IP | Negotiate mold ownership explicitly in the manufacturing contract |
| Chinese engineers often introduce undocumented changes to the layout | Design Integrity | Perform forensic design reviews or lab audits post-transfer |
| Golden samples don’t represent mass production quality | Quality Control | Insist on random sampling from real batches using third-party audits |
| Traceability is often fake or absent in small Chinese suppliers | Traceability | Build internal batch logs and serialization early in the transfer process |
| OEM test protocols usually don’t meet FDA/MDR validation standards | Compliance | Redesign test protocols under ISO 14971, 62304, and 13485 |
| Changing contract manufacturers? Re-do your EMC and electrical safety tests | Regulatory Testing | Schedule pre-compliance testing in the target region |
| Proprietary compilers = future IP trap | Firmware Architecture | Require use of open toolchains like GCC or IAR where possible |
| Always have your firmware lead interview the OEM’s lead directly | Communication | Use screen sharing, interpreters, and joint reviews to uncover hidden logic |
| Most early PCB failures stem from poor soldering temperature control | Failure Analysis | Ask for full thermal profile logs from reflow ovens and test runs |
| Build a shadow BOM with second-source suppliers before the transfer starts | Supply Chain | For each key component, list backup vendors and their lead times |
Key Success Factors in Manufacturing Transfer Support for Medtech Companies
- Early planning: Start assessing transfer feasibility 6-12 months before your current contract ends.
- Cross-functional expertise: Involve R&D, QA/RA, supply chain, and regulatory consultants.
- Clear ownership of IP: Make sure future contracts guarantee access to all source files and manufacturing know-how.
- Partner with experts: Choose a team with medtech-specific hardware, software, and regulatory experience.
Final Thoughts
Manufacturing transfer support for medtech companies is not a simple logistics exercise. It’s a high-stakes, multi-disciplinary project that can make or break your product’s long-term viability.
Whether you’re scaling, relocating due to policy shifts, or reclaiming your IP from overseas OEMs, the right strategy and technical partner can help you avoid delays, reduce costs, and protect your compliance posture.
If you’re considering a manufacturing transfer and want to de-risk the process, get in touch. We specialize in full-cycle hardware transition support—from teardown and documentation to pilot build and post-transfer innovation.
Want to learn more about specific aspects of our development process? Feel free to reach out. Innovation in medical device development is a journey best traveled together.
Book a call with CEO: https://calendly.com/lisa-voronkova/30min
430 Park Ave, New York, NY 10022, USA
Paevalille tn 6, Office 84, Estonia, Tallinn, 13517
Barykadna St 7, Dnipro, Ukraine, 49000